SG11202107510SA - Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells - Google Patents
Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cellsInfo
- Publication number
- SG11202107510SA SG11202107510SA SG11202107510SA SG11202107510SA SG11202107510SA SG 11202107510S A SG11202107510S A SG 11202107510SA SG 11202107510S A SG11202107510S A SG 11202107510SA SG 11202107510S A SG11202107510S A SG 11202107510SA SG 11202107510S A SG11202107510S A SG 11202107510SA
- Authority
- SG
- Singapore
- Prior art keywords
- hbv
- hla
- peptides
- virus
- cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5762—Hepatitis B core antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201900299V | 2019-01-11 | ||
| PCT/SG2020/050017 WO2020145901A1 (en) | 2019-01-11 | 2020-01-13 | Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107510SA true SG11202107510SA (en) | 2021-08-30 |
Family
ID=71522288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107510SA SG11202107510SA (en) | 2019-01-11 | 2020-01-13 | Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12414990B2 (en) |
| EP (1) | EP3908591A4 (en) |
| CN (1) | CN113939527B (en) |
| SG (1) | SG11202107510SA (en) |
| WO (1) | WO2020145901A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USD1083956S1 (en) * | 2018-12-10 | 2025-07-15 | Icahn School Of Medicine At Mount Sinai | Display screen with a graphical user interface |
| CN116364188A (en) * | 2023-03-30 | 2023-06-30 | 南开大学 | A system for uncoupling exhausted T cells in the tumor microenvironment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840303A (en) * | 1991-08-26 | 1998-11-24 | The Scripps Research Foundation | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| ZA926440B (en) * | 1991-08-26 | 1993-06-07 | Scripps Research Inst | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus. |
| US20030152580A1 (en) * | 1994-07-21 | 2003-08-14 | Alessandro Sette | Hla binding peptides and their uses |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| EP1064022A4 (en) * | 1998-03-13 | 2004-09-29 | Epimmune Inc | Hla-binding peptides and their uses |
| WO2009136874A1 (en) | 2008-05-09 | 2009-11-12 | Agency For Science, Technology And Research | Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof |
| CN102286075A (en) * | 2011-08-01 | 2011-12-21 | 中国人民解放军第三军医大学 | Hepatitis B virus surface antigen immunodominance HLA-A*1101 restricted cytotoxic T lymphocyte (CTL) epitope and use thereof |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| JP2016507520A (en) * | 2013-01-23 | 2016-03-10 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Stabilized hepatitis B core polypeptide |
| JP6743154B2 (en) * | 2016-01-12 | 2020-08-19 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) | Means and methods for treating HBV |
| US11576932B2 (en) * | 2016-03-31 | 2023-02-14 | Lion Tcr Pte. Ltd. | Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR) |
| MX2022003658A (en) * | 2019-09-30 | 2022-04-25 | Gilead Sciences Inc | VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND METHODS TO TREAT HBV. |
| WO2023146978A2 (en) * | 2022-01-26 | 2023-08-03 | Memorial Sloan-Kettering Cancer Center | Systems and methods for determining t-cell cross-reactivity between antigens |
-
2020
- 2020-01-13 SG SG11202107510SA patent/SG11202107510SA/en unknown
- 2020-01-13 EP EP20738835.6A patent/EP3908591A4/en active Pending
- 2020-01-13 US US17/421,816 patent/US12414990B2/en active Active
- 2020-01-13 WO PCT/SG2020/050017 patent/WO2020145901A1/en not_active Ceased
- 2020-01-13 CN CN202080019777.6A patent/CN113939527B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020145901A1 (en) | 2020-07-16 |
| US20230087348A1 (en) | 2023-03-23 |
| US12414990B2 (en) | 2025-09-16 |
| CN113939527B (en) | 2025-10-28 |
| CN113939527A (en) | 2022-01-14 |
| EP3908591A1 (en) | 2021-11-17 |
| EP3908591A4 (en) | 2023-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269927A (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
| IL323352A (en) | Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof | |
| IL274298A (en) | Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv) | |
| IL275427A (en) | Hepatitis b virus (hbv) vaccines and uses thereof | |
| SG10201914029RA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| WO2016055534A3 (en) | Combination therapy of hbv and hdv infection | |
| IL275429A (en) | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines | |
| EP3439696A4 (en) | THERAPEUTIC VACCINE FOR HEPATITIS B VIRUS (HBV) USING HBV NUCLEOCAPSIDIC ANTIGEN | |
| SG11202107510SA (en) | Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells | |
| IL288019A (en) | Compositions and methods for treating hepatitis b virus (hbv) infection | |
| SG11202005710YA (en) | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) | |
| MY191515A (en) | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof | |
| IL255366A0 (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
| EP3319997A4 (en) | IMMUNOGENIC COMPOSITIONS BASED ON HEPATITIS C VIRUS AND METHODS OF USE | |
| NZ751943A (en) | Hepatitis c virus immunogenic compositions and methods of use thereof | |
| IL290924A (en) | Hepatitis b virus vaccines | |
| EA201890187A1 (en) | RECOMBINANT VIRUS-LIKE PARTICLES (VLP) WITH THE USE OF THE PROTEIN GROUP ANTIGEN (GAG) OF THE BUCK IMMUNODEFICIENCY | |
| IL287227A (en) | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) | |
| EP4499684A4 (en) | Compositions and methods for inducing an immune response against EPSTEIN-BARR virus | |
| WO2016141201A3 (en) | Rational vaccine design for hepatitis c virus | |
| PT3491139T (en) | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens | |
| HK40074161A (en) | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof | |
| HK40039588A (en) | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) | |
| HK40046103A (en) | Hepatitis c virus peptide compositions and methods of use thereof | |
| HK40039938A (en) | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines |